Frontiers | Editorial: Innovations in development, translational research and manufacturing of CAR T cells As we witness the early stages of CAR-T cell therapy, the initial feedback underscores both its transformative potential and its current limitations. This no...

📢 Just out: a Frontiers research topic on innovations in #CARTcells featuring 2 IMI projects, T2Evolve & ImSAVAR! Discover:
☑️ how AI can progress CAR-T cell research
☑️ how to advance CAR-T therapy in Europe
☑️ how to improve CAR-T cell safety engineering
& more.
👉 www.frontiersin.org/journals/imm...

CAR T cells and T cell engagers for autoimmunity—lessons from hematology - Bone Marrow Transplantation Bone Marrow Transplantation - CAR T cells and T cell engagers for autoimmunity—lessons from hematology

"These observations underscore that eligibility for cellular immunotherapy should be guided by biological rather than chronological fitness—a principle of particular relevance for autoimmune diseases, which frequently affect older populations."
#Immunotherapy #Autoimmunity #CARTcells

Giving CAR T cells a portable pit crew Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes -- but on the go, within the tumor. The new genetic tweaks rewired CAR T cells to respond...

Published today in Science Immunology: @sriv4000.bsky.social and team find a new way to give #CARTcells their own portable pit crew, allowing them to rejuvenate on the go and transforms them into a type of T cell that can support long-term immune responses against tumors. https://bit.ly/3NiSged

CXCR4hi #CARTcells boost #TumorTracking, #BoneMarrow homing, and persistence, enhancing #Antitumor activity; early trial data in B cell malignancies show multiple complete responses, supporting #CXCR4 modification.

#OpenAccess in #STTT: doi.org/10.1038/s413...

ISBT Webinar: Let's talk CAR-T cells: cell heterogeneity, quality control and adverse events

Ideal for scientists, transfusion professionals, MDs, and MSc/PhD students.

www.isbtweb.org/events/isbt-...

#CARTcells #CellTherapy #TransfusionMedicine

The key insight here is sensitivity. Solid tumors are heterogeneous, and #HITcells appear able to detect what #CARTcells miss. If finding the last #cancer cell is the problem, this work points to a potential solution.
www.linkedin.com/posts/drmelv...

Optimizing CAR-T Cell Therapy to Tackle Solid Tumors.
Researchers at LMU Klinikum München, in close collaboration with University of Tübingen, have taken an important step forward.
Read:
medicalxpress.com/news/2026-02...
#Immunotherapy #CARTcells #Oncology #CellTherapy #CancerResearch

Great presentation by my colleague Heather Landau on transformative results of BCMA #CARTcells for #amyloidosis #tandem26 @mskcancercenter.bsky.social @mskdeptofmed.bsky.social

My @mskcancercenter.bsky.social colleague Dr Roisin E. O'Cearbhaill discussing role of cell therapy at #tandem26 Joint session @astct.bsky.social @sitcancer.bsky.social #tcellrx #cartcells

FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases As the first CAR-T treatment for an autoimmune disease dr | As the first CAR-T treatment for an autoimmune disease draws ever closer, the FDA’s Vinay Prasad, M.D., and colleagues have signaled a willi...

FDA reflections on #CARTCells therapies and autoimmunity: the key challenge is finding the match between the right product and the right indication.

www.fiercebiotech.com/biotech/fda-...

Scientists show that engineering #CARTcells to overexpress #CXCR4 restores #CXCL12-guided migration, enhances #tumortracking and #BoneMarrow homing, promotes memory persistence, and improves #antitumor efficacy in #BcellLymphoma and #myeloma.

#STTT: doi.org/10.1038/s413...

CAR-adapted PIK3CD base editing enhances T cell anti-tumor potency - Nature Cancer By performing a CAR-adapted base-editing screen of phosphatidylinositol-3-kinase delta (PI3Kδ, PIK3CD), Bucher et al. identify mutations affecting endogenous PI3K–AKT signaling that enhances CAR T cel...

🚀New paper alert and a great way to start the year for Philip and #TeamJJ!🚀 Our paper on enhancing T cell anti-tumor potency through CAR-adapted PIK3CD base editing is now out in Nature Cancer. For more details visit: www.nature.com/articles/s43...

#TeamJJ #NatureCancer #iFIT #CARTcells

CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596 SHANGHAI,Dec. 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted

Allogeneic #CARTCells in phase Ib/II clinical trials in China for the treatment of relapsed/refractory multiple myeloma (R/R MM) and primary plasma cell leukemia (pPCL). Phase I study showed interesting results.

buff.ly/SKuRXC9

Excited to share our paper that has been published in the @journalofnucmed.bsky.social
jnm.snmjournals.org/content/earl...
Our findings demonstrate the feasibility of PET-based CAR-T cell tracking in a solid tumor model through selective DOTA-hapten and Thor platform. #cartcells #immunotherapy

🚨 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗶𝗻 𝗖𝗔𝗥 𝗧-𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆!

Roswell Park researchers have developed IL-36 gamma “armored” CAR T cells that reprogram neutrophils to attack solid tumors.

🔗Read the full press release here: roswellpark.org/newsroom/202...

#CARTCells #RoswellPark

Kyverna to take autoimmune CAR-T to FDA after success in stiff person syndrome trial Kyverna Therapeutics' CAR-T therapy succeeded in a key study in stiff person syndrome, a rare autoimmune disorder that leads to painful muscle spasms and stiffness.

Kyverna to take autoimmune CAR-T to FDA after success in stiff person syndrome trial.
#CARTCells #Autoimmune disease

Researchers at @roswellpark.bsky.social Comprehensive #Cancer Center report in Cancer Cell that IL-36γ–armored #CARTcells can eradicate solid #tumors in preclinical models by reprogramming neutrophils and amplifying innate and adaptive anti #tumor #immunity.

www.linkedin.com/posts/drmelv...

Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia | NEJM CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of b...

Allogeneic anti-CD7 #CARTCells for relapsing T-ALL eradication prior to hematopoietic allograft!

Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia | New England Journal of Medicine buff.ly/7jYX07o

#ash25 early results in 4 patients with in vivo BCMA #CARTcells 2/2

Very impressive preliminary results of in vivo BCMA #CARTcells. High expansion of CART, excellent responses with low toxicity without lymphodepletion #ash25 #mmsm 1/2

Proud to share this elegant work by the very talented Dr. Edward Song on the engineered overexpression of CXCR3 in #CARTcells to drive better trafficking to pediatric brain & spinal tumors (beautiful art by www.katierisvicari.com) #VitanzaLab @seattlechildrens.org

www.nature.com/articles/s41...

⚡Our November issue is out! Featuring trials of #CARTcells for #LUPUS, an #ADC for #lungcancer, cardiac #genetherapy, an #ebola #vaccine, discovery of microbial elements in #braintumors, #liquidbiopsies, #newbornscreening, News, Reviews, & more.
https://www.nature.com/nm/volumes/31/issues/11

CSF1R-CAR T cells induce CSF1R signaling and can promote target cell proliferation Chimeric antigen receptor–stimulated responses in target cells may affect target cell clearance by CAR T cells.

A #ScienceSignaling study examines the activities of ligand-based #CARTcells and shows they induce proliferative signaling events within target cells, a finding that has implications for the design and application of future CAR T cells in the clinic. https://scim.ag/47CxSMB

Small-molecule control of CAR T cells - Nature Reviews Chemistry Chimeric antigen receptor (CAR) T cells are a promising and effective cancer therapy but are difficult to regulate once implanted. This Review covers an emerging wave of small-molecule-based systems d...

New in Nature Reviews Chemistry: Jason Lohmueller and colleagues review small-molecule control systems for #CARTCells — addressing toxicity & resistance challenges in #cancer #immunotherapy

Read the article: www.nature.com/articles/s41...

Jennifer Doudna startup launches with $82M to apply new CRISPR delivery technology to in vivo CAR-T Nobel laureate Jennifer Doudna's Azalea Therapeutics raises $82M to develop new CRISPR delivery system for in vivo CAR-T cell therapies targeting blood cancers.

Jennifer Doudna startup launches with $82M to apply new #CRISPR delivery technology to in vivo #CARTCells.

buff.ly/mewzZFL

#iPSC-derived, off-the-shelf anti-CD19 #CARTcells deliver improved clinical outcomes in lupus.

buff.ly/h2uH87G

As #ACRConvergence unfolds, one session really stood out “Driving CAR-T into the Future.”
With discussion of next-gen #Bcell targets (CD19, CD20, BCMA, autoreactive subsets), the field is moving from broad depletion to tailored immune precision.

#Lupus #AutoimmuneDisease #CARTcells

Epigenetics Update - Integrated epigenetic and genetic programming of primary human T cells go.nature.com/47AyUZd

#Epigenetic #Chromatin #TCells #CRISPR #CARTCells
---

Discover the breakthrough at epigenometech.com

🚀CAR-T cell therapy is showing promising results in #Brazil for lymphoma and leukemia patients, with survival rates of 73% and 79%. This advanced treatment offers new hope where other options have failed.
🔓https://doi.org/10.46765/2675-374X.2025v6n1p271

#CARTCells #CellTherapy #CancerTreatment

Sjoukje van der Stegen, from the Chan Zuckerberg Biohub New York share her works on iPS-derived #CARTCells.
#ITD2025